Avecho Biotechnology Limited (AVEFF)
USD 0.0
(157.14%)
USD 0.0
(157.14%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.32 Million AUD | -336.06% |
| 2022 | -1.22 Million AUD | 61.46% |
| 2021 | -3.17 Million AUD | -85.81% |
| 2020 | -1.7 Million AUD | 45.19% |
| 2019 | -3.11 Million AUD | -47.47% |
| 2018 | -2.11 Million AUD | 27.17% |
| 2017 | -2.89 Million AUD | 52.42% |
| 2016 | -6.09 Million AUD | 50.85% |
| 2015 | -12.39 Million AUD | 40.06% |
| 2014 | -20.67 Million AUD | -134.38% |
| 2013 | -8.82 Million AUD | 47.83% |
| 2012 | -16.91 Million AUD | 37.81% |
| 2011 | -27.19 Million AUD | -892.55% |
| 2010 | -2.74 Million AUD | 74.79% |
| 2009 | -10.86 Million AUD | 15.73% |
| 2008 | -12.89 Million AUD | -20.35% |
| 2007 | -10.71 Million AUD | 25.72% |
| 2006 | -14.42 Million AUD | -9.37% |
| 2005 | -13.18 Million AUD | -82.62% |
| 2004 | -7.22 Million AUD | -212.4% |
| 2003 | -2.31 Million AUD | -5.27% |
| 2002 | -2.19 Million AUD | 32.32% |
| 2001 | -3.24 Million AUD | 23.33% |
| 2000 | -4.23 Million AUD | -89.26% |
| 1999 | -2.23 Million AUD | -1360.0% |
| 1998 | -153.15 Thousand AUD | -14430.55% |
| 1997 | -1054.00 AUD | 99.42% |
| 1996 | -183 Thousand AUD | -128.75% |
| 1995 | -80 Thousand AUD | 72.97% |
| 1994 | -296 Thousand AUD | -101.36% |
| 1993 | -147 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.83 Million AUD | 9.21% |
| 2024 Q2 | -4.7 Million AUD | 2.84% |
| 2023 Q3 | -5.4 Million AUD | -103.45% |
| 2023 Q4 | -5.32 Million AUD | 1.42% |
| 2023 Q1 | -2.73 Million AUD | -123.46% |
| 2023 FY | -5.32 Million AUD | -336.06% |
| 2023 Q2 | -2.65 Million AUD | 2.7% |
| 2022 Q4 | -1.22 Million AUD | 5.48% |
| 2022 FY | -1.22 Million AUD | 61.46% |
| 2022 Q1 | -3.12 Million AUD | 1.31% |
| 2022 Q2 | -3.07 Million AUD | 1.73% |
| 2022 Q3 | -1.29 Million AUD | 57.95% |
| 2021 Q3 | -3.25 Million AUD | 29.67% |
| 2021 Q4 | -3.17 Million AUD | 2.47% |
| 2021 Q2 | -4.62 Million AUD | 1.72% |
| 2021 FY | -3.17 Million AUD | -85.81% |
| 2021 Q1 | -4.7 Million AUD | -175.63% |
| 2020 FY | -1.7 Million AUD | 45.19% |
| 2020 Q1 | -2.54 Million AUD | 18.16% |
| 2020 Q2 | -2.49 Million AUD | 2.09% |
| 2020 Q3 | -1.77 Million AUD | 28.67% |
| 2020 Q4 | -1.7 Million AUD | 4.1% |
| 2019 Q2 | -4.63 Million AUD | 1.1% |
| 2019 FY | -3.11 Million AUD | -47.47% |
| 2019 Q1 | -4.68 Million AUD | -122.14% |
| 2019 Q4 | -3.11 Million AUD | 2.79% |
| 2019 Q3 | -3.2 Million AUD | 30.95% |
| 2018 Q2 | -3.26 Million AUD | 0.0% |
| 2018 Q3 | -2.11 Million AUD | 35.37% |
| 2018 FY | -2.11 Million AUD | 27.17% |
| 2018 Q1 | -3.26 Million AUD | -12.69% |
| 2018 Q4 | -2.11 Million AUD | 0.0% |
| 2017 Q4 | -2.89 Million AUD | 0.0% |
| 2017 Q3 | -2.89 Million AUD | 28.1% |
| 2017 Q2 | -4.03 Million AUD | 0.0% |
| 2017 FY | -2.89 Million AUD | 52.42% |
| 2017 Q1 | -4.03 Million AUD | 33.83% |
| 2016 FY | -6.09 Million AUD | 50.85% |
| 2016 Q2 | -9.91 Million AUD | 0.0% |
| 2016 Q1 | -9.91 Million AUD | 20.01% |
| 2016 Q4 | -6.09 Million AUD | -0.01% |
| 2016 Q3 | -6.09 Million AUD | 38.56% |
| 2015 Q4 | -12.39 Million AUD | 0.0% |
| 2015 Q2 | -15.83 Million AUD | 0.0% |
| 2015 Q3 | -12.39 Million AUD | 21.71% |
| 2015 Q1 | -15.83 Million AUD | 23.44% |
| 2015 FY | -12.39 Million AUD | 40.06% |
| 2014 FY | -20.67 Million AUD | -134.38% |
| 2014 Q2 | -7.64 Million AUD | 0.0% |
| 2014 Q1 | -7.64 Million AUD | 13.41% |
| 2014 Q3 | -20.67 Million AUD | -170.67% |
| 2014 Q4 | -20.67 Million AUD | 0.0% |
| 2013 FY | -8.82 Million AUD | 47.83% |
| 2013 Q4 | -8.82 Million AUD | 0.0% |
| 2013 Q3 | -8.82 Million AUD | 37.4% |
| 2013 Q2 | -14.09 Million AUD | 0.0% |
| 2013 Q1 | -14.09 Million AUD | 16.66% |
| 2012 FY | -16.91 Million AUD | 37.81% |
| 2012 Q4 | -16.91 Million AUD | 0.0% |
| 2011 Q4 | -27.19 Million AUD | 0.0% |
| 2011 FY | -27.19 Million AUD | -892.55% |
| 2010 Q4 | -2.74 Million AUD | 0.0% |
| 2010 FY | -2.74 Million AUD | 74.79% |
| 2009 Q4 | -10.86 Million AUD | 0.0% |
| 2009 FY | -10.86 Million AUD | 15.73% |
| 2008 FY | -12.89 Million AUD | -20.35% |
| 2008 Q4 | -12.89 Million AUD | 0.0% |
| 2007 Q4 | -10.71 Million AUD | 0.0% |
| 2007 FY | -10.71 Million AUD | 25.72% |
| 2006 FY | -14.42 Million AUD | -9.37% |
| 2006 Q4 | -14.42 Million AUD | 0.0% |
| 2005 FY | -13.18 Million AUD | -82.62% |
| 2005 Q4 | -13.18 Million AUD | 0.0% |
| 2004 Q4 | -7.22 Million AUD | 0.0% |
| 2004 FY | -7.22 Million AUD | -212.4% |
| 2003 Q4 | -2.31 Million AUD | 0.0% |
| 2003 FY | -2.31 Million AUD | -5.27% |
| 2002 Q4 | -2.19 Million AUD | 0.0% |
| 2002 FY | -2.19 Million AUD | 32.32% |
| 2001 FY | -3.24 Million AUD | 23.33% |
| 2001 Q4 | -3.24 Million AUD | 0.0% |
| 2000 Q4 | -4.23 Million AUD | 0.0% |
| 2000 FY | -4.23 Million AUD | -89.26% |
| 1999 Q4 | -2.23 Million AUD | 0.0% |
| 1999 FY | -2.23 Million AUD | -1360.0% |
| 1998 Q4 | -153.15 Thousand AUD | 0.0% |
| 1998 FY | -153.15 Thousand AUD | -14430.55% |
| 1997 FY | -1054.00 AUD | 99.42% |
| 1997 Q4 | -1054.00 AUD | 0.0% |
| 1996 FY | -183 Thousand AUD | -128.75% |
| 1995 FY | -80 Thousand AUD | 72.97% |
| 1994 FY | -296 Thousand AUD | -101.36% |
| 1993 FY | -147 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | 380.647% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 133.809% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1426.181% |
| SQZ Biotechnologies Company | -36.23 Million USD | 85.294% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 337.676% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 112.454% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 15.47% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 674.776% |
| Marizyme, Inc. | 18.56 Million USD | 128.7% |
| Genus plc | 190.6 Million USD | 102.796% |
| Pharming Group N.V. | 109.8 Million USD | 104.853% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 719.506% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 539.023% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 883.713% |
| ContraFect Corporation | -6.02 Million USD | 11.562% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 561.235% |
| IMV Inc. | 7.67 Million USD | 169.477% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 196.862% |
| ONE Bio Corp. | 9.04 Million USD | 158.952% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 141.165% |
| Mesoblast Limited | 55.85 Million USD | 109.541% |
| MultiCell Technologies, Inc. | 90.04 USD | 5918852.777% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 117.442% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.498% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 956.291% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 628.844% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 229.413% |
| Biomind Labs Inc. | 711.4 Thousand USD | 849.119% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 366.543% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 141.613% |
| Skye Bioscience, Inc. | -5.72 Million USD | 6.854% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1581.539% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 338.356% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 3911.94% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 4058.173% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 194.35% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 26924.609% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -626.077% |
| EV Biologics, Inc. | 1.36 Million USD | 489.573% |
| Q BioMed Inc. | 4.06 Million USD | 231.262% |
| GB Sciences, Inc. | 1.74 Million USD | 404.996% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -2799.67% |
| CSL Limited | 10.52 Billion USD | 100.051% |
| Agentix Corp. | 37.63 Thousand USD | 14261.848% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 108.802% |
| Enzolytics Inc. | 981.65 Thousand USD | 642.883% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 182.611% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -691.759% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 342.02% |
| argenx SE | -2.02 Billion USD | 99.737% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 112.27% |
| HST Global, Inc. | 96.79 Thousand USD | 5605.817% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 88.664% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 2684.29% |
| Halberd Corporation | 144.72 Thousand USD | 3782.427% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 175.368% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 39.714% |
| Zenith Capital Corp. | 10.06 Thousand USD | 53053.547% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 296.752% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 323.352% |
| AVAX Technologies, Inc. | -5.9 Million USD | 9.723% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3339.485% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -28992.941% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 2758.879% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 344.633% |
| Helix BioMedix, Inc. | -2.57 Million USD | -107.361% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 126.284% |
| Kadimastem Ltd | -253.1 Thousand USD | -2005.572% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 219.169% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 2748.019% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -406712.595% |
| LadRx Corporation | -2.03 Million USD | -161.69% |
| Cell Source, Inc. | 9.23 Million USD | 157.726% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -26013.509% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 939.031% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 939.031% |
| Affymax, Inc. | -5.59 Million USD | 4.784% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1200.556% |
| Itoco Inc. | 228.3 Thousand USD | 2434.266% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 4018.879% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 207.509% |
| International Stem Cell Corporation | 2.59 Million USD | 305.762% |
| CytoDyn Inc. | 20.26 Million USD | 126.302% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -823585.471% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -57399.455% |
| Qrons Inc. | 351.42 Thousand USD | 1616.459% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 169.157% |
| SYBLEU INC | 473.71 Thousand USD | 1224.992% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2034.943% |
| Rebus Holdings, Inc. | 305 Thousand USD | 1847.293% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 219.57% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 8638.678% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 344.36% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 255.191% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 162.308% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 789.774% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -326.34% |
| Neutra Corp. | 52.18 Thousand USD | 10311.825% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -114.112% |
| PureTech Health plc | -167.19 Million USD | 96.813% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2076.019% |
| IXICO plc | -4.44 Million USD | -19.904% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 140.315% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 109.716% |
| CSL Limited | 10.52 Billion USD | 100.051% |
| Cellectis S.A. | -43.81 Million USD | 87.838% |